Sbihi H, Boutin RC, Cutler C, Suen M, Finlay BB, Turvey SE
It has already forced Novo Nordisk to lower prices of their brand-name drugs
Potential Benefits: The primary theoretical advantage is additive weight loss through different pathwaystirzepatide reducing appetite and caloric intake while orlistat blocks absorption of consumed dietary fat
All ingredients are tested for purity, sterility, and potency
Tolerance still varies with surgical recovery timeline and underlying metabolic health, so the decision belongs to your provider
While Health Canada didn't specifically say which brand-name medications are included in its review, the following will likely be under consideration, along with Ozempic: Novo Nordisk's Wegovy, which is approved in Canada for people with obesity but is not yet available to patients